Patent intelligence · AR
AR 065278
SALES DE DERIVADO DE BENZOTIAZOL
SALES DE DERIVADO DE BENZOTIAZOL
Patent details — AR 065278
- Jurisdiction
- AR
- Status
- granted
- Grant date
- May 27, 2009
- Expiration
- May 22, 2029
- Applicant
- ASTRAZENECA AB [SE]
- CPC classes
- A61K/31428, A61K31/428, A61P/1100, A61P/1102
Quick answer
AR 065278 (SALES DE DERIVADO DE BENZOTIAZOL) is held by ASTRAZENECA AB [SE]. Status: granted. Granted May 27, 2009. Expires May 22, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTRAZENECA AB [SE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K/31428, A61K31/428, A61P/1100, A61P/1102, A61P/1106, A61P/4300
More from ASTRAZENECA AB [SE]
Related pharmaceutical patents in our USPTO index.
-
IL 240179
Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject
granted -
ZA 201308176
THERAPEUTIC TREATMENT
granted -
SI 2158199
PIPERIDINE COMPOUNDS AND USES THEREOF
granted -
US 2010280048
Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
granted -
DO P2009000148
DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES
granted -
EP 2086964
BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN
granted -
EP 2079730
MGLUR5-MODULATOREN
granted -
EP 2064340
VERFAHREN ZUR BEWERTUNG VON PATIENTEN BEI DER BEHANDLUNG MIT AUF RET-REZEPTOR-TYROSINKINASE ABZIELENDEN ARZNEISTOFFEN
granted
Frequently asked questions
What is US patent 065278?
AR 065278 (SALES DE DERIVADO DE BENZOTIAZOL) is held by ASTRAZENECA AB [SE]. Status: granted. Granted May 27, 2009. Expires May 22, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns AR 065278?
ASTRAZENECA AB [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does AR 065278 expire?
Our index shows an expiration date of May 22, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.